Orforglipron (Foundayo)

Orforglipron, FDA-approved April 1, 2026 under the brand name Foundayo, is the first non-peptide (small molecule) oral GLP-1 receptor agonist approved in the United States -- and the first oral GLP-1 for weight loss that can be taken any time of day, with or without food, water, or timing restrictions. Unlike oral semaglutide (which requires SNAC absorption enhancers and strict 30-minute fasting), orforglipron is a small molecule that bypasses GI peptide degradation entirely -- a major real-world adherence advantage for patients who cannot reliably fast in the morning or travel frequently. In the ATTAIN-1 Phase 3 trial (N=3,127, 72 weeks, 10 countries), orforglipron at its highest dose (36 mg) achieved 12.4% average body weight loss in the adherent population (11.1% full population) versus 0.9% placebo. Average absolute weight loss approximately 27.3 pounds. A head-to-head diabetes trial showed orforglipron delivered superior blood sugar control and weight loss vs oral semaglutide (Rybelsus). Side effects: nausea, constipation, diarrhea, vomiting, indigestion, headache, fatigue -- consistent GLP-1 class effects. Cost: Medicare Part D $50/month from July 1, 2026. Commercial savings card: as low as $25/month. Self-pay: $149/month (lowest dose) via LillyDirect. Available from April 6, 2026 at retail pharmacies and telehealth platforms.